SR One leads $55M round for nasal alternative to EpiPen; Sanofi pulls website over accuracy concerns

California-based biopharma company ARS Pharmaceuticals said today that they have closed on a Series D round of $55 million. The round was led by SR One, with RA Capital Management and Deerfield Management participating.

ARS is using the money to advance its drug Neffy, an epinephrine...

Click to view original post